Skip to player
Skip to main content
Skip to footer
Search
Log in
Sign up
Watch fullscreen
Like
Comments
Bookmark
Share
Add to Playlist
Report
Biogen Plunges After FDA Says No to Alzheimer's Treatment
The Street
Follow
11/9/2020
Biogen stock plunges more than 30% after a Food and Drug Administration panel committee rules against giving the company's Alzheimer's drug the nod.
Category
🥇
Sports
Show less
Recommended
0:39
|
Up next
FDA Approves Eli Lilly's Alzheimer's Drug, Slowing the Progression of the Brain-Wasting Disease
Benzinga
1:30
FDA approves new Alzheimer’s drug from Eli Lilly
The Street
0:43
FDA Approves First Drug to Target Genetic Cause of ALS
Benzinga
10:41
Novel Therapy Shows Promising Results In On-Going Trials, Receives 3 Orphan Drug Designations From The FDA
Benzinga
16:00
This Biotech Just Cleared A Big FDA Hurdle In Its Quest To Improve ADHD Treatment
Benzinga
1:00
Medical advancements: New drug found to slow decline of Alzheimer’s by 35% in trial
Local TV
0:48
Biogen Alzheimer's drug closer to approval
PDA Media
2:24
Biggest Pharmaceuticals Mergers And Acquisition in History
The Street
3:50
Landmark trial shows new drug can slow Alzheimer’s disease
ABC NEWS (Australia)
5:04
Families impacted by Alzheimer's express concerns over new drug Leqembi
23ABC News
0:42
FDA Bans Red Dye No. 3 Effective January 2027, Cites Cancer Risks
Benzinga
1:58
Dementia At the End of Life: What are the medications?
Healthfeedspanish
0:48
New drug breakthrough gives hope for those with Alzheimer's
ODN
1:00
Alzheimer's: New drug dubbed 'beginning of the end' in search for treatment
National World - LocalTV
1:49
Drug trial shows treatment slows progress of disease
ABC NEWS (Australia)
0:46
Trump’s Approval Rating Hits Historic Low
Cheddar News
0:28
Chinese Manufacturers Shifting Focus Due to U.S. Tariffs
Cheddar News
0:41
Merck To Buy SpringWorks Therapeutics For $3.9 Billion, Marking Major Expansion
Benzinga
0:36
Airline CEOs Warn Of Slowing Domestic Demand, Blame Economic Uncertainty And Trump Tariffs
Benzinga
0:43
PayPal, Block, And Affirm Face Pressure Ahead Of Earnings As Consumer Spending Risks Rise Under Trump’s Tariffs
Benzinga
5:21
Inside The Epic Battle Between Danone And Lifeway Foods—And Its Squabbling Founding Family
Forbes
5:13
Elon Musk Is Running Out Of Ideas To Save Tesla
Forbes
4:43
Pete Hegseth Hates DEI. His Deputy Put Tens Of Millions Into It.
Forbes
0:42
Jersey Mike's Gets New CEO After 50 Years
Cheddar News
0:58
Foreign travelers are not coming to the U.S.
The Street